Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Choudhary Sobhan Shakeel
 + 1079 word(s) 1079 2022-01-18 06:42:08 |
2 update layout and reference
Rita Xu
 Meta information modification 1079 2022-01-28 10:17:42 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Shakeel, C.S. Global COVID-19 Vaccine Acceptance. Encyclopedia. Available online: https://encyclopedia.pub/entry/18951 (accessed on 02 May 2024).
Shakeel CS. Global COVID-19 Vaccine Acceptance. Encyclopedia. Available at: https://encyclopedia.pub/entry/18951. Accessed May 02, 2024.
Shakeel, Choudhary Sobhan. "Global COVID-19 Vaccine Acceptance" Encyclopedia, https://encyclopedia.pub/entry/18951 (accessed May 02, 2024).
Shakeel, C.S. (2022, January 28). Global COVID-19 Vaccine Acceptance. In Encyclopedia. https://encyclopedia.pub/entry/18951
Shakeel, Choudhary Sobhan. "Global COVID-19 Vaccine Acceptance." Encyclopedia. Web. 28 January, 2022.
Global COVID-19 Vaccine Acceptance
Edit
This entry is adapted from the peer-reviewed paper 10.3390/vaccines10010110

COVID-19 vaccines have met varying levels of acceptance and hesitancy in different parts of the world, which has implications for eliminating the COVID-19 pandemic. 

COVID-19 vaccine acceptance vaccine hesitancy associated factors

1. Introduction

The COVID-19 pandemic has impacted many aspects of our everyday lives and changed the socio-economic fabric of the entire world [1][2][3][4]. The COVID-19 disease is caused by the highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and, at the time of its outbreak, no vaccine was available to prevent individuals from contracting the infection. Therefore, countries had to take stringent measures in order to contain the infection, including nation-wide lockdowns and border closures [5][6][7][8]. Along with countries implementing lockdowns, home-healthcare services were also optimized in order to cater to the needs of COVID-19 patients at their homes in case they either did not require hospitalization or could not be admitted to hospitals due to a lack of patient beds or other vital medical facilities [9][10]. Multi-objective home-healthcare services involving the use of artificial-intelligence models were introduced, ensuring patient availability and convenience [9]. Furthermore, home-healthcare supply-chain frameworks have also been introduced based on programming models that aid patients in selecting pharmacies, enhance the selection and routing of nurses and also help caregivers connect with patients in a timely manner [10]. Despite these protective measures, the coronavirus continued to spread and harm individuals including children, the elderly and people with medical conditions such as cancer, diabetes and respiratory diseases, who were also at the highest risk of contracting the infection [5][11][12][13]. Individuals who required access to routine medical services such as pregnant women and people with chronic conditions experienced mental health issues such as stress, depression and reduced emotional well-being [14][15][16][17]. The emotional well-being of parents and children also suffered due to the lack of educational and food resources and the enhanced stress and financial problems due to restricted and insufficient healthcare facilities, especially in less-developed countries [18][19][20][21][22]. Due to the overwhelming number of positive cases and the limited availability of medical devices, the pressure on healthcare workers (HCWs) has significantly increased and placed them at higher risk of contracting the contagion. Several studies have reported clinically significant depression, stress and decreased mental well-being in HCWs [23][24]. Due to these numerous harmful effects of the COVID-19 virus, there is a crucial need to develop and administer vaccines in order to eliminate this deadly pandemic [24][25].
The Coalition for Epidemic Preparedness Innovations (CEPI) has been cooperating with the World Health Organization (WHO) to aid the vaccine developers in successfully developing and deploying COVID-19 vaccines [26]. The rapid development of the COVID-19 vaccine was seen as a necessity to suppress the repeated infection waves and lower the mortality rate [27]. The COVID-19 vaccine-development efforts started in March 2020 with the first vaccine candidate entering human trials on 16 March 2020. On 4 January 2021, the United Kingdom (U.K.) became the first country to administer a COVID-19 vaccine, which was manufactured by AstraZeneca in association with Oxford University [28]. Soon, other countries started their own vaccine campaigns. For example, China administered vaccines developed by home manufacturers such as Sinopharm, Sinovac and Cansino Biologica; Russia administered its vaccine known as Sputnik V; and the United States (U.S.) has been using vaccines developed by home manufacturers including Pfizer-BioNTech, Moderna, and Johnson and Johnson [28]. The rapid and sustained administration of the COVID-19 vaccine is critical for the world to return to the pre-pandemic normalcy. As of November 2021, one hundred and seventy-five vaccines are in clinical trials, forty-one have been approved and reached the final testing phase, and seventy-five are undergoing animal trials. Although the current progress in vaccine development and administration is encouraging, social-distancing and face-mask mandates are still in place in various regions to counteract the infection [29][30][31]. This is because, to be effective, the COVID-19 vaccines must be administered to the majority of the world population [32]. However, variations in vaccine acceptance and hesitancy have been observed in different groups across the world [33]. This means that the world, at large, is at risk of yet another pandemic as new SARS-CoV-2 variants continue to emerge.

2. Characteristics of the Papers Included

81 papers were selected for this systematic review, with the most papers being from China (n = 12), followed by Italy (n = 8) and then the U.S (n = 8). Also included in this review were studies conducted in Saudi Arabia (n = 5), France (n = 4), Hong Kong (n = 4), Turkey (n = 4) and the U.K. (n = 4). While the majority of the studies were published in 2020, the most recent paper was published in June 2021. Six studies involved more than one country. Neumann-Böhme et al. [34] published a study spanning seven European countries, Lazarus et al. [35] focused on nineteen countries, and the research of Bono et al. [36] was conducted in nine countries. Taylor et al. [37], Salali and Uysal [38] and Sallam et al. [39] conducted their studies in two countries each. All of the studies focused on adults, with the exception of Zhang et al. [40], who worked with children below 18 years of age. Among the included studies, 57 surveys included the general population and 16 included HCWs. Three studies focused on multiple groups including the general population, HCWs and healthcare college students [41][42][43]. Two studies focused solely on dentists, dental surgeons and dental students [44]. Lazarus et al. [35] had the largest sample size (n = 13,426), while Mascarenhas et al. [44] had the smallest (n = 248). A total of fifty countries that reported their COVID-19 vaccine-acceptance rates are highlighted in Figure 1.
Vaccines 10 00110 g002 550
Figure 1. Map illustrating vaccine-acceptance rates worldwide.

3. Rates of COVID-19 Vaccine Acceptance

The mean COVID-19 vaccine-acceptance rates of countries are illustrated in Figure 2. Indonesia (93.30%) had the highest mean vaccine-acceptance rate followed by Egypt (90.50%), Brazil (87.15%), South Africa (85.85%), Ecuador (84.45%) and Denmark (80%). The means and standard deviations for the continents are shown in Figure 3. We found that the highest mean vaccine-acceptance rate was reported by South America (78.44%), whereas the lowest mean vaccine-acceptance rate was reported in Africa (56.59%).
Vaccines 10 00110 g003 550
Figure 2. Worldwide COVID-19 vaccine-acceptance rates.
Vaccines 10 00110 g004 550
Figure 3. Mean and standard deviation of COVID-19 vaccine-acceptance rates for continents.
Among adults from the general population, the highest vaccine-acceptance rates were reported in Ecuador (97%), Malaysia (94.3%) and Indonesia (93.3%), and the lowest rate was reported in Lebanon (21.40%). In the healthcare workers (HCWs) category, general HCWs in China (86.20%) and nurses in Italy (91.50%) had the highest acceptance rates. The HCWs in the Democratic Republic of Congo had the lowest acceptance rate (27.70%). Among the patients with chronic diseases, those with rheumatic disease in Turkey showed a vaccine-acceptance rate of 29.2%, adolescent cancer survivors in the U.S. had an acceptance rate of 63%, and patients with type-two diabetes mellitus in Italy reported an acceptance rate of 85.80%. One study based in China reported a 77.4% vaccine-acceptance rate among pregnant women.

References

  1. Pišot, S.; Milovanović, I.; Šimunič, B.; Gentile, A.; Bosnar, K.; Prot, F.; Bianco, A.; Lo Coco, G.; Bartoluci, S.; Katović, D.; et al. Maintaining everyday life praxis in the time of COVID-19 pandemic measures (ELP-COVID-19 survey). Eur. J. Public Health 2020, 30, 1181–1186.
  2. Lades, L.K.; Laffan, K.; Daly, M.; Delaney, L. Daily emotional well-being during the COVID-19 pandemic. Br. J. Health Psychol. 2020, 25, 902–911.
  3. Patrick, S.W.; Henkhaus, L.E.; Zickafoose, J.S.; Lovell, K.; Halvorson, A.; Loch, S.; Letterie, M.; Davis, M.M. Well-being of parents and children during the COVID-19 pandemic: A national survey. Pediatrics 2020, 146, 1–8.
  4. Aslam, F.; Awan, T.M.; Syed, J.H.; Kashif, A.; Parveen, M. Sentiments and emotions evoked by news headlines of coronavirus disease (COVID-19) outbreak. Hum. Soc. Sci. Commun. 2020, 7, 1–9.
  5. Dariya, B.; Nagaraju, G.P. Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients. Cytokine Growth Factor Rev. 2020, 53, 43–52.
  6. Lake, M.A. What we know so far: COVID-19 current clinical knowledge and research. Clin. Med. 2020, 20, 124.
  7. Dey, S.K.; Rahman, M.M.; Siddiqi, U.R.; Howlader, A. Analyzing the epidemiological outbreak of COVID-19: A visual exploratory data analysis approach. J. Med. Virol. 2020, 92, 632–638.
  8. Koh, D. COVID-19 lockdowns throughout the world. Occup. Med. 2020, 70, 322.
  9. Fathollahi-Fard, A.M.; Ahmadi, A.; Karimi, B. Multi-Objective Optimization of Home Healthcare with Working-Time Balancing and Care Continuity. Sustainability 2021, 13, 12431.
  10. Fathollahi-Fard, A.M.; Hajiaghaei-Keshteli, M.; Tavakkoli-Moghaddam, R.; Smith, N.R. Bi-level programming for home health care supply chain considering outsourcing. J. Ind. Inf. Integr. 2021, 25, 100246.
  11. Al-Quteimat, O.M.; Amer, A.M. The impact of the COVID-19 pandemic on cancer patients. Am. J. Clin. Oncol. 2020, 43, 452–455.
  12. Richards, M.; Anderson, M.; Carter, P.; Ebert, B.L.; Mossialos, E. The impact of the COVID-19 pandemic on cancer care. Nat. Cancer 2020, 1, 565–567.
  13. Shafaghi, A.H.; Talabazar, F.R.; Koşar, A.; Ghorbani, M. On the effect of the respiratory droplet generation condition on COVID-19 transmission. Fluids 2020, 5, 113.
  14. Deprest, J.; Choolani, M.; Chervenak, F.; Farmer, D.; Lagrou, K.; Lopriore, E.; McCullough, L.; Olutoye, O.; Simpson, L.; Van Mieghem, T.; et al. Fetal diagnosis and therapy during the COVID-19 pandemic: Guidance on behalf of the international fetal medicine and surgery society. Fetal Diagn. Ther. 2020, 47, 689–698.
  15. Caparros-Gonzalez, R.A.; Ganho-Ávila, A.; Torre-Luque, A.d.l. The COVID-19 Pandemic Can Impact Perinatal Mental Health and the Health of the Offspring; Multidisciplinary Digital Publishing Institute: Basel, Switzerland, 2020.
  16. Sade, S.; Sheiner, E.; Wainstock, T.; Hermon, N.; Yaniv Salem, S.; Kosef, T.; Lanxner Battat, T.; Oron, S.; Pariente, G. Risk for depressive symptoms among hospitalized women in high-risk pregnancy units during the COVID-19 pandemic. J. Clin. Med. 2020, 9, 2449.
  17. Ceulemans, M.; Hompes, T.; Foulon, V. Mental health status of pregnant and breastfeeding women during the COVID-19 pandemic: A call for action. Int. J. Gynecol. Obstet. 2020, 151, 146–147.
  18. Bates, L.C.; Zieff, G.; Stanford, K.; Moore, J.B.; Kerr, Z.Y.; Hanson, E.D.; Barone Gibbs, B.; Kline, C.E.; Stoner, L. COVID-19 impact on behaviors across the 24-h day in children and adolescents: Physical activity, sedentary behavior, and sleep. Children 2020, 7, 138.
  19. Xue, A.; Oros, V.; Marca-Ghaemmaghami, P.L.; Scholkmann, F.; Righini-Grunder, F.; Natalucci, G.; Karen, T.; Bassler, D.; Restin, T. New parents experienced lower parenting self-efficacy during the COVID-19 pandemic lockdown. Children 2021, 8, 79.
  20. Chang, C.-L.; McAleer, M.; Wong, W.-K. Risk and Financial Management of COVID-19 in Business, Economics and Finance; Multidisciplinary Digital Publishing Institute: Basel, Switzerland, 2020.
  21. Singer, D.R. Health policy and technology challenges in responding to the COVID-19 pandemic. Health Policy Technol. 2020, 9, 123.
  22. Angrup, A.; Kanaujia, R.; Ray, P.; Biswal, M. Healthcare facilities in low-and middle-income countries affected by COVID-19: Time to upgrade basic infection control and prevention practices. Indian J. Med. Microb. 2020, 38, 139–143.
  23. Pappa, S.; Ntella, V.; Giannakas, T.; Giannakoulis, V.G.; Papoutsi, E.; Katsaounou, P. Prevalence of depression, anxiety, and insomnia among healthcare workers during the COVID-19 pandemic: A systematic review and meta-analysis. Brain Behav. Immun. 2020, 88, 901–907.
  24. Spoorthy, M.S.; Pratapa, S.K.; Mahant, S. Mental health problems faced by healthcare workers due to the COVID-19 pandemic–A review. Asian J. Psychiatry 2020, 51, 102119.
  25. Chatzittofis, A.; Karanikola, M.; Michailidou, K.; Constantinidou, A. Impact of the COVID-19 Pandemic on the Mental Health of Healthcare Workers. Int. J. Environ. Res. Public Health 2021, 18, 1435.
  26. Andreadakis, Z.; Kumar, A.; Román, R.G.; Tollefsen, S.; Saville, M.; Mayhew, S. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 2020, 19, 305–306.
  27. Graham, B.S. Rapid COVID-19 vaccine development. Science 2020, 368, 945–946.
  28. Zhao, J.; Zhao, S.; Ou, J.; Zhang, J.; Lan, W.; Guan, W.; Wu, X.; Yan, Y.; Zhao, W.; Wu, J.; et al. COVID-19: Vaccine Development Updates. Front. Immunol. 2020, 11, 3435.
  29. Yan, Y.; Pang, Y.; Lyu, Z.; Wang, R.; Wu, X.; You, C.; Zhao, H.; Manickam, S.; Lester, E.; Wu, T.; et al. The COVID-19 vaccines: Recent development, challenges and prospects. Vaccines 2021, 9, 349.
  30. Kumar, A.; Dowling, W.E.; Román, R.G.; Chaudhari, A.; Gurry, C.; Le, T.T.; Tollefson, S.; Clark, C.E.; Bernasconi, V.; Kristiansen, P.A. Status report on COVID-19 vaccines development. Curr. Infect. Dis. Rep. 2021, 23, 1–12.
  31. Prüβ, B.M. Current state of the first COVID-19 vaccines. Vaccines 2021, 9, 30.
  32. Mannan, D.K.A.; Farhana, K.M. Knowledge, attitude and acceptance of a COVID-19 vaccine: A global cross-sectional study. Int. Res. J. Bus. Soc. Sci. 2020, 6, 1–23.
  33. Feleszko, W.; Lewulis, P.; Czarnecki, A. Waszkiewicz Flattening the curve of COVID-19 vaccine rejection—An international overview. Vaccines 2021, 9, 44.
  34. Neumann-Böhme, S.; Varghese, N.E.; Sabat, I.; Barros, P.P.; Brouwer, W.; van Exel, J.; Schreyögg, J.; Stargardt, T. Once We Have It, Will We Use It? A European Survey on Willingness to Be Vaccinated against COVID-19; Springer: Berlin/Heidelberg, Germany, 2020.
  35. Lazarus, J.V.; Ratzan, S.C.; Palayew, A.; Gostin, L.O.; Larson, H.J.; Rabin, K.; Kimball, S.; El-Mohandes, A. A global survey of potential acceptance of a COVID-19 vaccine. Nat. Med. 2021, 27, 225–228.
  36. Bono, S.A.; Faria de Moura Villela, E.; Siau, C.S.; Chen, W.S.; Pengpid, S.; Hasan, M.T.; Sessou, P.; Ditekemena, J.D.; Amodan, B.O.; Hosseinipour, M.C.; et al. Factors Affecting COVID-19 Vaccine Acceptance: An International Survey among Low-and Middle-Income Countries. Vaccines 2021, 9, 515.
  37. Taylor, S.; Landry, C.A.; Paluszek, M.M.; Groenewoud, R.; Rachor, G.S.; Asmundson, G.J. A proactive approach for managing COVID-19: The importance of understanding the motivational roots of vaccination hesitancy for SARS-CoV-2. Front. Psychol. 2020, 11, 2890.
  38. Salali, G.D.; Uysal, M.S. COVID-19 vaccine hesitancy is associated with beliefs on the origin of the novel coronavirus in the UK and Turkey. Psychol. Med. 2020, 50, 1–3.
  39. Sallam, M.; Dababseh, D.; Eid, H.; Al-Mahzoum, K.; Al-Haidar, A.; Taim, D.; Yaseen, A.; Ababneh, N.A.; Bakri, F.G.; Mahafzah, A. High rates of COVID-19 vaccine hesitancy and its association with conspiracy beliefs: A study in Jordan and Kuwait among other Arab countries. Vaccines 2021, 9, 42.
  40. Zhang, K.C.; Fang, Y.; Cao, H.; Chen, H.; Hu, T.; Chen, Y.Q.; Zhou, X.; Wang, Z. Parental acceptability of COVID-19 vaccination for children under the age of 18 years: Cross-sectional online survey. Jmir Pediatr. Parent. 2020, 3, e24827.
  41. Al-Metwali, B.Z.; Al-Jumaili, A.A.; Al-Alag, Z.A.; Sorofman, B. Exploring the acceptance of COVID-19 vaccine among healthcare workers and general population using health belief model. J. Eval. Clin. Pract. 2021, 27, 1112–1122.
  42. Dror, A.A.; Eisenbach, N.; Taiber, S.; Morozov, N.G.; Mizrachi, M.; Zigron, A.; Srouji, S.; Sela, E. Vaccine hesitancy: The next challenge in the fight against COVID-19. Eur. J. Epidemiol. 2020, 35, 775–779.
  43. Yurttas, B.; Poyraz, B.C.; Sut, N.; Ozdede, A.; Oztas, M.; Uğurlu, S.; Tabak, F.; Hamuryudan, V.; Seyahi, E. Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: A web-based survey. Rheumatol. Int. 2021, 41, 1105–1114.
  44. Mascarenhas, A.K.; Lucia, V.C.; Kelekar, A.; Afonso, N.M. Dental students’ attitudes and hesitancy toward COVID-19 vaccine. J. Dent. Educ. 2021, 85, 1504–1510.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Education & Educational Research; Demography; Behavioral Sciences
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Choudhary Sobhan Shakeel
View Times: 448
Entry Collection: COVID-19
Revisions: 2 times (View History)
Update Date: 28 Jan 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback